By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

LEO Pharma 

Industriparken 55
DK-2750 Ballerup
Copenhagen      Denmark
Phone: 45-4492-3800 Fax: 45-4494-3040


SEARCH JOBS


Industry
Pharmaceutical






Company News
LEO Pharma Announced New Taclonex® (Calcipotriene And Betamethasone Dipropionate) Topical Suspension, 0.005%/0.064% Indication For Treatment Of Scalp Plaque Psoriasis In Pediatric Patients Ages 12-17 9/30/2014 10:00:58 AM
LEO Pharma & Klox Technologies Strike Global Dermatology Deal 7/15/2014 8:52:07 AM
Antares Pharma, Inc. (ATRS) Receives Second Milestone Payment From LEO Pharma In OTREXUP Collaboration 3/12/2014 7:11:07 AM
Antares Pharma, Inc. (ATRS) Announces LEO Pharma’s Launch Of OTREXUP (Methotrexate) Injection To Dermatologists For Adults With Psoriasis 3/10/2014 9:00:25 AM
Antares Pharma, Inc. (AIS) Enters Into An Exclusive U.S. Promotion And Marketing Agreement With LEO Pharma For OTREXUP™ In Dermatology 11/14/2013 9:26:16 AM
LEO Pharma Expands QualityCare™ Patient Support Program 10/28/2013 11:14:44 AM
LEO Pharma Puts Patients at the Heart of Innovation 3/19/2013 10:14:23 AM
Virobay Inc. and LEO Pharma Initiate a Phase 1 Trial of VBY-891, a Compound Intended for Oral Treatment of Psoriasis 3/18/2013 10:12:23 AM
LEO Pharma Receives FDA Approval for Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064% for Body Plaque Psoriasis 10/26/2012 12:40:41 PM
LEO Pharma Initiates Global Search for New Partners 6/14/2012 11:41:06 AM
123456
//-->